ArQule, Inc. (NASDAQ:ARQL)
| CAPS Rating |
|
|---|---|
| Open | $7.81 |
| Previous Close | $7.87 |
| Daily Range | $7.69 - $7.84 |
| 52-Week Range | $3.98 - $8.19 |
| Market Cap | $415.31M |
| P/E Ratio | 0.00 |
| Dividend (Yield) | N/A (N/A) |
| Volume | 218,964 |
| Average Daily Volume | 0 |
ARQL
VS S&P 500 (SPY)
How do you think ARQL will perform against the market?
Caps
Motley Fool CAPS is a community working together to find better stocks and to become better investors.
ARQL Advanced Details
- CAPS Community Analysis: Commentary, Scorecard
- Advanced Financial Analysis: Historical Prices, Chart, Stats, Ratios, Earnings/Growth Rates, Statements, SEC Filings
ARQL News and Commentary
- Company News for January 18, 2012 - Corporate Summary – NASDAQ
- ArQule Earnings Preview – The Motley Fool
- Why SuperGen's Earnings Are Outstanding – The Motley Fool
- 3 Biotechs With Momentum Ahead of ASCO – SeekingAlpha
- 52 Stocks Worth Watching That Hit 52 Week Highs Last Friday – SeekingAlpha
- Future Biotech Superstars – SeekingAlpha
- Here's How SuperGen Is Making You So Much Cash – The Motley Fool
- 30 Small Cap Stocks With Conservative Accounting Practices – SeekingAlpha
- 3 Clear Winners of ESMO 2010 – SeekingAlpha
- Pfizer's Failure Provides Clarity for Arqule – SeekingAlpha
- Jury Still Out on Exelixis's Long Term Potential – SeekingAlpha
- Tomorrow's Monster Stock – The Motley Fool
- UPDATE 1-ArQule drug works best in certain lung cancers – Reuters
- ArQule drug works best in certain lung cancers – Reuters
- PREVIEW-Investors seek clarity on ArQule trial plan – Reuters
- 3 Stocks Shaking the Market – The Motley Fool
- UPDATE 1-ArQule cancer drug shows promise in trial; shrs soar – Reuters
- ArQule, Inc.: Warming Up or Cooling Off? – The Motley Fool
- UPDATE 1- ArQule Q3 beats estimates, sees narrower '09 loss – Reuters
- 6 Stocks Losing Top Investor Support – The Motley Fool
RSS Headlines
Fool UK
